Last quarter (Q2 2023), Checkpoint Therapeutics's total revenue was $31.00K, an increase of 72.22% from the same quarter last year. In Q2, Checkpoint Therapeutics's net income was $-16.52M. See Checkpoint Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	$ 188.00K	$ 192.00K	$ 268.00K	$ 1.07M	$ 1.71M	$ 3.51M
Cost of Revenue	-	-	-	-	-	-
Gross Profit	$ 140.00K	$ 192.00K	$ 268.00K	-	-	-
Operating Expense	$ 28.34M	$ -58.52M	$ 56.99M	$ 24.27M	$ 26.56M	$ 40.25M
Operating Income	$ -61.59M	$ -58.33M	$ -56.72M	$ -23.20M	$ -24.85M	$ -36.74M
Net Non Operating Interest Income Expense	$ 3.31M	$ -4.29M	$ 53.00K	$ 120.00K	$ 136.00K	$ 148.00K
Other Income Expense	$ 357.00K	-	-	-	-	$ 225.00K
Pretax Income	$ -58.63M	$ -62.62M	$ -56.67M	$ -23.08M	$ -24.71M	$ -36.37M
Tax Provision	-	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -58.63M	$ -62.62M	$ -56.67M	$ -23.08M	$ -24.71M	$ -36.37M
Basic EPS	$ -9.75	$ -7.09	-	$ -0.41	$ -0.70	$ -1.27
Diluted EPS	$ -10.15	$ -7.09	$ -7.50	$ -0.41	$ -0.70	$ -1.27
Basic Average Shares	$ 45.14M	$ 8.84M	$ 7.60M	$ 55.83M	$ 35.30M	$ 28.55M
Diluted Average Shares	$ 45.14M	$ 8.84M	$ 7.60M	$ 55.83M	$ 35.30M	$ 28.55M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 28.34M	$ -58.52M	$ 56.99M	$ 24.27M	$ 26.56M	$ 40.25M
Net Income From Continuing And Discontinued Operation	$ -58.63M	$ -62.62M	$ -56.67M	$ -23.08M	$ -24.71M	$ -36.37M
Normalized Income	$ -23.66M	-	-	$ -23.08M	$ -24.71M	$ -36.37M
Interest Expense	-	-	-	-	-	-
EBIT	$ -54.30M	$ -62.62M	$ -56.67M	$ -23.20M	$ -24.85M	$ -36.74M
EBITDA	$ -54.30M	$ -62.62M	$ -56.67M	$ -23.20M	$ -24.85M	$ -36.74M

Currency in USD

Checkpoint Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing